EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Role of Serum Free Fatty Acids in Endothelium‐Dependent Microvascular Function

Alexander E Sullivan iD, Meaghan C S Courvan, Aaron W Ada, David H Wasserman, Kevin D Niswender, Emily M Shardelow, Emily K Wells, Quinn S Wells, Matthew S Freiberg, Joshua A Beckman iD

Endocrinology, Diabetes & Metabolism · 2025

DOI: 10.1002/edm2.70031 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Endocrinology, Diabetes & Metabolism, 2025. Verfasst von Alexander E Sullivan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA. Hauptthemen laut MEDLINE: Endothelium, Vascular, Fatty Acids, Nonesterified, Metabolic Syndrome, Vasodilation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, American Diabetes Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Elevated serum free fatty acid (FFA) concentration is associated with insulin resistance and is a hallmark of metabolic syndrome. A pathological feature of insulin resistance is impaired endothelial function.

Objective

To investigate the effect of FFA reduction with either acipimox, a nicotinic acid derivative that impairs lipolysis, or salsalate, a salicylate that reduces basal and inflammation‐induced lipolysis, on insulin‐mediated endothelium‐dependent vasodilation.

Methods

This was a post hoc, combined analysis of two randomised, double‐blind, placebo‐controlled crossover trials. Sixteen subjects were recruited (6 with metabolic syndrome and 10 controls) and randomised to acipimox 250 mg orally every 6 h for 7 days or placebo. Nineteen subjects were recruited (13 with metabolic syndrome and 6 controls) and randomised to receive salsalate 4.5 g/day for 4 weeks or placebo. The primary outcome was the association between FFA concentration and insulin‐mediated vasodilation, measured by venous‐occlusion strain‐gauge plethysmography at baseline and following FFA modulation with the study drugs.

Results

At baseline, FFA concentration ( R = −0.35, p = 0.043) and insulin sensitivity (HOMA‐IR: R = −0.42, p = 0.016, Adipo‐IR: R = −0.39, p = 0.025) predicted insulin‐mediated vasodilation. FFA levels were significantly reduced after drug pretreatment (0.604 vs. 0.491 mmol/L, p = 0.036) while insulin levels, insulin sensitivity and inflammatory markers were unchanged. Despite a reduction in circulating FFA with drug therapy, neither insulin‐stimulated vasodilation nor insulin sensitivity improved.

Conclusions

Short‐term reduction of FFA concentration does not improve insulin‐stimulated vasodilation in patients with metabolic syndrome. Trial Registration ClinicalTrials.gov identifier: NCT00759291 and NCT00760019 (formerly NCT00762827)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelium, VascularFatty Acids, NonesterifiedMetabolic SyndromeVasodilationAdultFemaleHumansMaleMiddle AgedCross-Over StudiesDouble-Blind MethodInsulinInsulin ResistanceOxadiazolesSalicylatesPyrazines

Stichwörter der Autor:innen

endothelial functionfree fatty acidinsulin sensitivityinsulin‐mediated vasodilationmetabolic syndrome

Substanzen

acipimoxFatty Acids, NonesterifiedInsulinOxadiazolesSalicylatessalicylsalicylic acidPyrazines

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Biochemistry, University of Colorado, Boulder, Colorado, USA.
  • Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Department of Veteran Affairs, Tennessee Valley Healthcare System, Nashville, Tennessee, USA.

ORCID-Profile: Alexander E Sullivan, Joshua A Beckman

Förderung

  • NIH HHS
  • NIGMS NIH HHS
  • American Diabetes Association
  • NHLBI NIH HHS
  • National Institutes of Health

Zitieren

APA

Sullivan, A. E., Courvan, M. C. S., Ada, A. W., Wasserman, D. H., Niswender, K. D., Shardelow, E. M., Wells, E. K., Wells, Q. S., Freiberg, M. S., & Beckman, J. A. (2025). The Role of Serum Free Fatty Acids in Endothelium‐Dependent Microvascular Function. Endocrinology, Diabetes & Metabolism. https://doi.org/10.1002/edm2.70031

Vancouver

Sullivan AE, Courvan MCS, Ada AW, Wasserman DH, Niswender KD, Shardelow EM, et al. The Role of Serum Free Fatty Acids in Endothelium‐Dependent Microvascular Function. Endocrinology, Diabetes & Metabolism. 2025. doi:10.1002/edm2.70031

BibTeX
@article{Sullivan2025,
  author = {Sullivan, Alexander E and Courvan, Meaghan C S and Ada, Aaron W and Wasserman, David H and Niswender, Kevin D and Shardelow, Emily M and Wells, Emily K and Wells, Quinn S and Freiberg, Matthew S and Beckman, Joshua A},
  title = {The Role of Serum Free Fatty Acids in Endothelium‐Dependent Microvascular Function},
  journal = {Endocrinology, Diabetes & Metabolism},
  year = {2025},
  doi = {10.1002/edm2.70031}
}
Kostenlos starten →